ArticleMikrochimica acta2026
Ultra-hydrophilic MXene nanoplatform unraveling plasma N-glycopeptide in epidural-related maternal fever.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Given the high incidence of epidural‑related maternal fever (ERMF) among women with epidural analgesia and the key roles of glycoproteins, an efficient nanoplatform is needed for N‑glycoproteomic analysis to better understand ERMF. Herein, we constructed an ultra-hydrophilic magnetic MXene-based nanoplatform (MMX-Cys) for efficient N-glycopeptide enrichment. By integrating the high surface area of MXene, the hydrophilicity of L-cysteine, MMX-Cys demonstrated ultra-hydrophilicity with a water contact angle of ~ 0°. It exhibits high sensitivity (1 fmol·µL⁻¹), excellent selectivity (HRP: BSA = 1:100), and good reproducibility in enriching glycopeptides from standard protein digests. Applied to plasma samples from ERMF patients and healthy controls, the MMX-Cys based nanoplatform enabled the identification of 1195 N-glycopeptides corresponding to 91 glycoproteins. Differential expression analysis revealed 18 significantly altered glycopeptides from 10 glycoproteins, predominantly involved in humoral immunity and complement activation, including immunoglobulin heavy chains (IGHG1, IGHG2, IGHA1, IGHA2) and complement component C2. This study presents an effective tool for N-glycopeptide determination and provides glycoproteomic evidence supporting the inflammatory pathogenesis of ERMF. The MMX-Cys based nanoplatform holds great potential in offering a foundation for future biomarker discovery and mechanistic studies.
Indexed as
Identifiers
42277438What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.